Palleon Pharmaceuticals Announces First Patient Dosed with E-602 in Combination with Cemiplimab in GLIMMER-01 Phase 1/2 Clinical Trial

On June 22, 2023 Palleon Pharmaceuticals, a clinical-stage company pioneering glyco-immunology drug development to treat cancer and inflammatory diseases, reported that the first patient has been dosed in the combination therapy cohort of the Phase 1/2 clinical trial for E-602, its lead candidate from the EAGLE (Enzyme Antibody Glyco-Ligand Editing) oncology platform (Press release, Palleon Pharmaceuticals, JUN 22, 2023, View Source [SID1234632863]). The GLIMMER-01 (Glycan-Mediated Immune Regulation) trial is designed to study E-602 as a monotherapy and in combination with cemiplimab (anti-PD-1) in patients with advanced cancers.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"With E-602, we are investigating an entirely new approach to oncology, one that we feel has potential benefits both as a monotherapy and in combination with other anti-cancer agents," said Jim Broderick, M.D., Chief Executive Officer and Founder of Palleon. "We are pleased to work with Regeneron to evaluate E-602 in combination with cemiplimab. We expect this trial to provide valuable information as we look to understand the benefits that targeting sialoglycans can bring to advancing the field of oncology and ultimately improving the outlook for patients."

E-602 is a first-in-class glyco-immune checkpoint inhibitor developed by Palleon and designed to enzymatically degrade immunosuppressive cell-surface sugars on tumors and immune cells. GLIMMER-01 is an open-label, single-arm, dose-escalation, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic, and antitumor activity of E-602. Regeneron is providing cemiplimab for the trial as part of a clinical supply agreement initiated earlier this year.

Palleon recently announced Phase 1 results from the GLIMMER-01 trial of E-602 as a monotherapy at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2023 in Orlando, Florida. The study demonstrated proof of mechanism for E-602, including dose dependent desialylation and dose dependent immune system activation. Additionally, E-602 was found to be well tolerated across the entire dose range evaluated with no dose limiting toxicities.